



Cardiac Autonomic Neuropathy in Non-Diabetic Patients with Chronic Kidney Disease

Thesis

Submitted for Partial Fulfillment of Master Degree
In Internal Medicine

By

Mahmoud El Nemr Mohammed
(M.B.,B.Ch.)

Supervised by

Prof. Dr. Gamal El Sayed Mady

*Professor of Internal Medicine and Nephrology
Faculty of Medicine - Ain Shams University*

Dr. Maha Abd El Moneim Behairy

*Lecturer of Internal Medicine and Nephrology
Faculty of Medicine - Ain shams University*

Dr. Ahmad El Sayed Yousef

*Lecturer of Cardiology
Faculty of Medicine - Ain shams University*

*Faculty of Medicine
Ain Shams University*

2017



First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.

I wish to express my deepest thanks, gratitude and appreciation to *Prof. Dr. Gamal El Sayed Mady*, Professor of Internal Medicine and Nephrology Faculty of Medicine - Ain Shams University for his meticulous supervision, kind guidance, valuable instructions and generous help.

Special thanks are due to *Dr. Maha Abd El Moneim Behairy*, Lecturer of Internal Medicine and Nephrology Faculty of Medicine - Ain shams University for her sincere efforts, fruitful encouragement.

I am deeply thankful to *Dr. Ahmad El Sayed Yousef*, Lecturer of Cardiology Faculty of Medicine - Ain shams University for his great help, outstanding support, active participation and guidance.

Mahmoud El Kemr Mohammed

List of Contents

Title	Page No.
List of Tables	i
List of Figures.....	iii
List of Abbreviations	v
Introduction	1
Aim of the Work	12
Review of Literature	
▪ Cardiac Autonomic Neuropathy (CAN) in Chronic Kidney Disease (CKD)	13
▪ Management of Cardiac Autonomic Neuropathy	60
Subjects and Methods.....	77
Results	85
Discussion.....	110
Summary	119
Conclusion	122
Recommendations	123
References	124
Arabic summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Interpretation of autonomic function tests (AFT) as normal, borderline or abnormal depending on the value of the parameter measured and score as points are given in bracket	20
Table (2):	Manifestation of Cardiac Autonomic Neuropathy.	41
Table (3):	Relation of CAN score with age and therapeutic correction of CAN	73
Table (4):	Interpretation of autonomic function tests as normal, borderline or abnormal.....	81
Table (5):	Reference ranges & partition values for left ventricular mass indexed to BSA (g/m ²)	82
Table (6):	Comparison between the three studied groups according to demographic and clinical characteristics.....	85
Table (7):	Etiology of CKD among studied patient groups.	87
Table (8):	Comparison between the three studied groups according to laboratory data.	88
Table (9):	Comparison between the three studied groups according to ECHO.....	91
Table (10):	Distribution of the studied cases according to Symptoms of autonomic neuropathy in cases group (n=50).	92
Table (11):	Comparison between the two studied groups according to symptoms of cardiac autonomic neuropathy	93
Table (12):	Comparison between the three studied groups according to cardiac autonomic dysfunction.....	95
Table (13):	Comparison between the two studied groups according to cardiac autonomic dysfunction.....	97

List of Tables cont...

Table No.	Title	Page No.
Table (14):	Relation between cardiac autonomic dysfunction with demographic data and ECHO cardiograph studied parameters.	99
Table (15):	Relation between cardiac autonomic dysfunction with laboratory data.	100
Table (16):	Relation between cardiac autonomic dysfunction with eGFR.	102
Table (17):	Relation between cardiac autonomic dysfunction with Protein / Creatinine ratio.....	103
Table (18):	Relation between cardiac autonomic dysfunction with Symptoms of autonomic neuropathy	104
Table (19):	Comparison between the two studied groups according to test 1 (Valsalva ratio).	106
Table (20):	Comparison between the two studied groups according to test 2 (R-R interval).	107
Table (21):	Comparison between the two studied groups according to test 3 (30:15 ratio).	108
Table (22):	Comparison between the two studied groups according to test 4.	109

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Prevalence rate ratios and 95% confidence intervals for the association between cardiac autonomic neuropathy (CAN) and silent myocardial ischemia (MI) in 12 studies. Modified from Vinik et al.	14
Figure (2):	Electrocardiography during respiratory cycles with maximal inspiration and expiration used for calculation of beat-to-beat variation.	18
Figure (3):	Deep breathing tests cardiac parasympathetic function	18
Figure (4):	Natural progression of CAN and correlation with clinical signs and symptoms. CAN: Cardiac autonomic neuropathy; LV: Left ventricle.	21
Figure (5):	Prevalence of nephropathy in type 2 diabetic patients with early CAN.	22
Figure (6):	Stages of cardiovascular autonomic neuropathy.	22
Figure (7):	Cumulative incidence of cardiovascular death of the study participants according to the presence of cardiac autonomic neuropathy (CAN).	31
Figure (8):	Stages of cardiovascular autonomic neuropathy	32
Figure (9):	Symptoms of autonomic dysfunction in CRF patients.	37
Figure (10):	Pathogenesis of sudomotor dysfunction.	39
Figure (11):	Clinical features of diabetic autonomic neuropathy.	41
Figure (12):	Heart rate variability.	43
Figure (13):	Prevalence of silent MI.	46

List of Figures cont...

Fig. No.	Title	Page No.
Figure (14):	Association between CAN and silent myocardial infarction.....	47
Figure (15):	A. Normal QT interval B. Prolonged or abnormal QT interval.....	48
Figure (16):	Mortality rate from MI.....	50
Figure (17):	Peripheral autonomic neuropathy symptoms.....	51
Figure (18):	The autonomic nervous system.....	52
Figure (19):	Relation of CAN to CKD & BMI.	57
Figure (20):	Cumulative survival rates of the study participants according to the presence of cardiac autonomic neuropathy (CAN).	76
Figure (21):	Symptoms of autonomic neuropathy among non-diabetic CKD patients groups	92
Figure (22):	Relation between symptoms of autonomic neuropathy and cardiac autonomic dysfunction.....	94
Figure (23):	Cardiac autonomic neuropathy dysfunctions among Non-diabetic CKD patients.....	96
Figure (24):	Relation between symptoms of autonomic neuropathy and autonomic dysfunction in Total patients.....	98
Figure (25):	Relation between autonomic dysfunction with Hemoglobin level.....	101
Figure (26):	Relation between autonomic dysfunction with Total cholesterol.....	101
Figure (27):	Relation between autonomic dysfunction with eGFR	102
Figure (28):	Relation between autonomic dysfunction with Symptoms of cardiac autonomic neuropathy	105

List of Abbreviations

Abb.	Full term
<i>ACEI</i>	<i>Angiotensin converting enzyme inhibitors</i>
<i>AF</i>	<i>Atrial fibrillation</i>
<i>AFT</i>	<i>Autonomic function tests</i>
<i>AN</i>	<i>Autonomic neuropathy</i>
<i>ANS</i>	<i>Autonomic nervous system</i>
<i>ARB</i>	<i>Angiotensin receptor blockers</i>
<i>BP</i>	<i>Blood pressure</i>
<i>bpm</i>	<i>Beats per minute</i>
<i>BRR</i>	<i>Baroreceptor reflex</i>
<i>CAD</i>	<i>Coronary artery disease</i>
<i>CAN</i>	<i>Cardiac autonomic neuropathy</i>
<i>CKD</i>	<i>Chronic kidney disease</i>
<i>CV</i>	<i>Cardiovascular</i>
<i>CVD</i>	<i>Cardiovascular disease</i>
<i>CVS</i>	<i>Cardiovascular system</i>
<i>DBP</i>	<i>Diastolic blood pressure</i>
<i>eGFR</i>	<i>Estimated glomerular filtration rate</i>
<i>ESRD</i>	<i>End Stage Renal Disease</i>
<i>GFR</i>	<i>Glomerular filtration rate</i>
<i>GI</i>	<i>Gastrointestinal</i>
<i>GU</i>	<i>Genitourinary</i>
<i>HR</i>	<i>Heart rate</i>
<i>HRV</i>	<i>Heart rate variability</i>
<i>HTN</i>	<i>Hypertension</i>
<i>LUTS</i>	<i>Lower urinary tract symptoms</i>
<i>LV</i>	<i>Left ventricle</i>
<i>LV</i>	<i>Left ventricular</i>
<i>MI</i>	<i>Myocardial ischemia</i>
<i>PNS</i>	<i>Parts of the ANS-parasympathetic</i>

List of Abbreviations cont...

Abb.	Full term
<i>PTH</i>	<i>Parathyroid hormone</i>
<i>PVR</i>	<i>Postvoid residual volume</i>
<i>QDIRT</i>	<i>Quantitative direct and indirect reflex test</i>
<i>SBP</i>	<i>Systolic blood pressure</i>
<i>SMI</i>	<i>Silent myocardial ischemia</i>
<i>SNS</i>	<i>Sympathetic Nervous System</i>

Abstract

There were no significant correlation between type of cardiac autonomic dysfunction & demographic data. Most of the patients were males with mean age 44.78 ± 13.11 years.

There were no significant correlation between type of cardiac autonomic dysfunction & echocardiography.

There were no significant correlation between types of autonomic dysfunction regarding laboratory data, except for definite parasympathetic dysfunction which has a significant correlation with hemoglobin (anemia) & cholesterol level (hypercholesterolemia).

There were no significant correlation between types of cardiac autonomic dysfunction & decrease GFR, but the lowest GFR were detected in definite parasympathetic.

There was no significant correlation between types of CAN & protein / creatinine ratio.

Keywords: Sympathetic Nervous System- Silent myocardial ischemia- Systolic blood pressure- Parathyroid hormone

Abstract

INTRODUCTION

Cardiovascular autonomic neuropathy (CAN) is associated with high risk of sudden cardiac death. CAN is been diagnosed based on the early symptoms of neuropathy and autonomic dysfunction. These symptoms may include orthostatic dizziness, gastrointestinal (GI) and genitourinary (GU) symptoms, and hypoglycemia unawareness or unresponsiveness (*Vinik and Ziegler, 2007*).

CAN is preceded by autonomic dysfunction. The process of aging is a factor which causes autonomic decline, which in turn leads to autonomic neuropathy. The earlier the autonomic dysfunction is detected, the greater the number of therapy options. Advanced autonomic dysfunction may be more difficult to treat. In other words, it is easier to correct early stage autonomic dysfunction compared than advanced-stage autonomic neuropathic damage (*Vinik and Ziegler, 2007*).

The main function of the autonomic nervous system (ANS) is to maintain homeostasis, regardless of the conditions. The two main branches of the ANS, the parasympathetic and the sympathetic, can dynamically adjust their input to maintain homeostasis and apparent normal even in the face of degraded end-organ function. Often these ANS adjustments result in autonomic imbalance and begin to affect other systems within the body, including the cardiovascular system. This is the basis for the constellation of symptoms known to degrade quality of life in

many chronic diseases. By the time symptoms present as a result of end-organ dysfunction or failure, the ANS has been out of balance for considerably longer (*Vinik and Ziegler, 2007*).

Unfortunately, early signs of autonomic dysfunction are often not recognized due to two main reasons. First, the current understanding of the effects of the ANS and its interaction with other physiological systems is incomplete. Second, a reliable clinical tool to measure and monitor the ANS did not exist until recently, when the ability to measure both ANS branches simultaneously and independently was developed commercially (ANSAR Medical Technologies, Inc., Philadelphia, PA). Prior to this, autonomic neuropathy could be clinically diagnosed (orthostatic hypotension, gastro-paresis, etc.) only at an advanced stage with dramatic symptoms. At this stage, it is usually much too late for anything but treatment of the symptoms. With simultaneous, independent measures of both ANS branches, these patients can be identified even when they are still asymptomatic, or mildly symptomatic, a fairly common situation usually accompanied by fatigue, light-headedness, palpitations, intractable hypertension, etc. Therapeutic intervention seems to improve outcomes by slowing or halting autonomic decline and the associated disease progression (*Vinik et al., 2007*).

The history of non-invasive ANS monitoring in clinical practice is confusing. Traditionally, it has been based only on measures of heart rate variability (HRV). Measures of HRV

defined in the 1996 Circulation standards article, 3 are mixed or incomplete measures of the parasympathetic and the sympathetic. This is not surprising regardless of how much it is dissected. But, one independent measure of a system (the ANS) that contains two components: the parasympathetic and the sympathetic. From a mathematical perspective, one measure is insufficient to fully characterize a two-component system. If one measure changes, it is impossible to determine which component changed without making assumptions or without additional information. This has resulted in a very low clinical acceptance rate for this method. Except in extreme cases, HRV alone provides no additional information. The use of HRV alone merely indicates the obvious: that the patient's ANS is functioning (*Task Force of the European Society of Cardiology, 1996*).

AIM OF THE WORK

The aim of the work is to evaluate the pattern of cardiac autonomic neuropathy (CAN) in non-diabetic chronic kidney disease (CKD) patients not on dialysis.